Clinical trial · Interventional
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
NCT01342679CI-TRIAL-00019119CMR-CMLcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate complete molecular response of Dasatinib in patients for Philadelphia chromosome-positive chronic myeloid leukemia
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dasatinib | Drug | Dasatinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- dasatinib
- interventionNames
- Drug: dasatinib
Primary outcomes (1)
- measure
- Rate of complete molecular response (CMR) after treatment with dasatinib
- timeFrame
- at 12 months
Secondary outcomes (4)
- measure
- Dasatinib of dose intensity
- timeFrame
- at 12 months
- measure
- Expansions rate of large granular lymphocyte
- timeFrame
- at 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Chronic Myeloid Leukemia in the Chronic Phase * 20 years old over * ECOG performance status (PS) score 0-2 * Patients for major molecular response (MMR) with no CMR * Adequate organ function (hepatic, renal and lung) * Signed written informed consent Exclusion Criteria: * A case with the double cancer of the activity * Women who are pregnant or breastfeeding * The case of Pleural effusion clearly * Patients with complications or a history of severe or uncontrolled cardiovascular failure following * have a Myocardial infarction within 6 months * have an Angina within 3 months * have a Congestive heart failure within 3 months * have a suspected congenital QT syndrome * have a QTc interval of more than 450msec at baseline * A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy * Prior treatment with dasatinib * Subjects with T315I, F317L and V299L BCR-ABL point mutations
References
Publications (0)
Data not yet available
No reference posted for this study.